CLL | Tumor

Traditional Definition of ‘High-Risk’ in Patients With CLL and SLL Outdated, Needs to be Revisited

December 7th 2020, 2:00pm

In an interview with CURE®, Dr. Jan A. Burger discusses how the results of two phase 3 studies could help redefine what constitutes as low or high risk in patients with CLL or SLL.

Venclexta-Rituxan Combo Continues to Show Survival Benefit Through 5 Years in Relapsed/Refractory CLL

December 5th 2020, 9:33pm

Compared with patients assigned bendamustine with Rituxan, those assigned Venclexta with Rituxan maintained an overall survival benefit, with a five-year OS estimate of 82.1% for the Venclexta with Rituxan group vs. 62.2% for the bendamustine with Rituxan group.

Data Support Fixed-Treatment Duration of Imbruvica/Venclexta Combo Could Lead to Treatment Discontinuation in Certain Patients With CLL/SLL

December 5th 2020, 9:07pm

Data suggest that patients with CLL/SLL who achieve confirmed undetectable minimal residual disease following 12 cycles of Imbruvica combined with Venclexta could possibly discontinue and reasonably remain off treatment.

When and How CLL, SLL Should Be Treated

November 5th 2020, 10:00pm

New treatment options are outperforming the “old-fashioned” chemotherapy regimens for patients with CLL and SLL, according to Dr. Locke J. Bryan.

Progression-Free Survival, Overall Survival Sustained at Four Years with Venclexta Plus Rituxan in Patients With CLL

November 4th 2020, 10:00pm

This benefit observed with Venclexta (venetoclax) plus Rituxan (rituximab) for patients with CLL was particularly strong in patients with undetectable minimal residual disease, which may predict clinical outcome after chemoimmunotherapy.

Understanding the Pendulum Swing in CLL Research Over the Last Decade

October 15th 2020, 3:00pm

In this episode of the “CURE Talks Cancer” podcast, we spoke with an expert from Dana-Farber Cancer Institute in Boston about the results of an early-phase clinical trial that assessed the efficacy of a combination therapy in the frontline setting in patients with CLL aged 65 years and younger, as well as a pendulum swing in research over the last decade.

Treating With Venetoclax for Chronic Lymphocytic Leukemia: Samantha’s Story

October 14th 2020, 4:00am

Keeping Calm and Carrying on With CLL

October 5th 2020, 5:00pm

CLL patient shares his experience with the disease and the importance of aiming to live his life to the fullest despite his diagnosis.

Clinical Trials are Fueling Medical Breakthroughs in Cancer

September 24th 2020, 6:00pm

Clinical trials lead to new cancer treatments — and can give a patient access to effective drugs years before they’re made available to the public.

Register For the Next EDUCATED PATIENT® CLL Webinar

September 23rd 2020, 7:18pm

On Thursday, September 30, 2020, from 5:30 – 6:30 p.m. ET join CURE® for the next EDUCATED PATIENT® CLL Webinar.